GlaxoSmithKline said its increasingly streamlined operations are on a growth trajectory, but that capacity constraints mean demand for its popular shingles vaccine will keep outstripping supply.
GlaxoSmithKline PLC beat forecasts with better-than-expected third-quarter results 30 October, as robust sales of its shingles vaccine Shingrix, its HIV franchise, and some older drugs allowed the UK’s biggest drug maker to increase its 2019 profit forecast for the second time this year.
GSK now expects 2019 Adjusted EPS (earnings per share) to be roughly flat when measured in constant exchange rates (CER)....
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.
BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.
